Clinical summary
Summary
Eligible participants will receive immunotherapy (cemiplimab) at a dose of 250mg intravenously every 3 weeks for up to 12 weeks. This study has primarily a translational research objective with the clinical component conducted as a prospective, single arm open label study.Treatment Type
Radiotherapy,Systemic therapy (chemotherapy, hormone therapy or immunotherapy)Age
18+
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Peter MacCallum Cancer Centre
Scientific Title
Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients